Filter
1317
Text search:
adverse
drug
event
Featured
169
338
Language
Document type
772
243
150
75
36
17
12
6
3
1
1
1
Countries / Regions
87
41
38
31
29
27
24
21
18
18
18
17
17
14
14
12
12
11
11
11
9
9
9
9
8
8
8
7
6
6
5
5
5
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
408
225
88
71
33
24
23
1
Toolboxes
139
135
130
72
65
45
40
38
30
30
23
18
16
15
14
12
10
8
7
6
4
2
1
Blueprint for EECA countries, first edition
17–24 November 2015
4–15 February 2013
14–22 April 2015
For the Fiscal Year 2015-2016, the Health Sector continued to implement actions meant to improve the availability, and access to quality healthcare. The following report highlights achievements registered by the health sector for the fiscal 2015-2016 in different health programs, as well as in the a
...
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle ...
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle ...
National Tuberculosis Programme and Senior Paediatricians
This guideline was first developed in 2007 but further updated in 2012 and 2016 to ensure the use of the latest evidence-based international recommendations on childhood TB. The guidelines will fill the gaps in a systematic approach to T ...
This guideline was first developed in 2007 but further updated in 2012 and 2016 to ensure the use of the latest evidence-based international recommendations on childhood TB. The guidelines will fill the gaps in a systematic approach to T ...
Draft for consultation
Guidelines for malaria vector control
recommended
these guidelines are updated on 16 February 2021
Please check the new guideline here
https://medbox.org/document/who-guidelines-for-malaria#GO
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
A tool for measuring alcohol policy implementation
Rapid review and case studies from Member States
Anxiety disorders
Chapter F.1
2018 edition
Anxiety disorders
Chapter F.2
Paediatrics
Chapter I.2
Externalizing disorders
Chapter 1.1
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?
